Clearside Biomedical Inc
NASDAQ:CLSD

Watchlist Manager
Clearside Biomedical Inc Logo
Clearside Biomedical Inc
NASDAQ:CLSD
Watchlist
Price: 0.929 USD 5.6% Market Closed
Market Cap: 70.5m USD
Have any thoughts about
Clearside Biomedical Inc?
Write Note

Clearside Biomedical Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Clearside Biomedical Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Clearside Biomedical Inc
NASDAQ:CLSD
Revenue
$7.7m
CAGR 3-Years
26%
CAGR 5-Years
95%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%
No Stocks Found

Clearside Biomedical Inc
Glance View

Market Cap
69.4m USD
Industry
Pharmaceuticals

Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.

CLSD Intrinsic Value
0.529 USD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Clearside Biomedical Inc's Revenue?
Revenue
7.7m USD

Based on the financial report for Sep 30, 2024, Clearside Biomedical Inc's Revenue amounts to 7.7m USD.

What is Clearside Biomedical Inc's Revenue growth rate?
Revenue CAGR 5Y
95%

Over the last year, the Revenue growth was 249%. The average annual Revenue growth rates for Clearside Biomedical Inc have been 26% over the past three years , 95% over the past five years .

Back to Top